By InvitationNot Applicable

The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.

Poland100 participantsStarted 2023-06-01

Plain-language summary

The participants in the study will be adult patients with suspected sleep-disordered breathing. A one-night polysomnography will be performed using the NOXA1 device (NOX Medical, Reykjavík, Iceland). During the polysomnographic examination, sleep, breathing, heart rate and activity of the masticatory muscles will be recorded. Blood sample will be taken from each of the participants qualified to the study and control group to determine the level of dopamine and used to perform genetic tests of selected single nucleotide polymorphisms occurring within the genes regulating the concentration of dopamine and genes encoding dopamine receptors.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age between 18 and 80 years old * suspicion of sleep-disordered breathing Exclusion Criteria: * age under 18 * age over 80 * severe disorders and systemic diseases (including genetical disorders) * neurological disorders * active inflammations * active cancer * severe mental disorders and retardation (including genetical) * taking drugs that could falsify polysomnography * confirmed alcoholism * drug addiction * pregnancy and breast feeding * treatment using or dependence on any painkillers and/or drugs and substances that may affect nervous, muscular and respiratory system functions * lack of consent to participate in the study

What they're measuring

Relationship between sleep-disordered breathing and blood dopamine level.

Timeframe: June 1, 2023 - December 31, 2023

Trial details

NCT IDNCT05890911

SponsorWroclaw Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Sleep Apnea trials